Top

Published in:

01-02-2016 | Editorial

Imaging and chemotherapy cardiotoxicity: A long-playing story still seeking precision and improved outcomes/management data

Author: William A. Van Decker, MD

Published in: Journal of Nuclear Cardiology | Issue 1/2016

Excerpt

Doctors have always recognized that every patient is unique, and doctors have always tried to tailor their treatments as best as they can to individuals. … What if figuring out the right dose of medicine was as simple as taking our temperature?

…

Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.CrossRefPubMed

Minow R, Benjamin R, Gottlieb J. Adriamycin cardiomyopathy: An overview with determination of risk factors. Cancer Chemother Rep 1975;6:195-201.

Perik P, deKorte A, van Veldhulsen D, Gietema JA, Sleijfer DT, De Vries E. Cardiotoxicity associated with the use of Trastuzumab in breast cancer patients. Expert Rev Anticancer Ther 2007;7:1763-71.CrossRefPubMed

Piccart-Gebhart M, Proctor M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. NEJM 2005;353:1659-72.CrossRefPubMed

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2 positive breast cancer. NEJM 2011;365:1273-83.PubMedCentralCrossRefPubMed

Perez E, Ramond E, Suman V, Jeong JH, Davidson NE, Geyer CE, et al. Four year follow up of Trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2 positive breast cáncer: Joint Analysis of data from NCCTG N 9831 and NSABP B—31. J Clin Oncol 2011;20:3366-73.CrossRef

Alexander J, Dainiak N, Berger H, Goldman l, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. NEJM 1979;300:278-83.CrossRefPubMed

Bristow M, Mason J, Billingham M, Daniels JR. Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978;88:168-75.CrossRefPubMed

Choi B, Berger H, Schwartz P, Alexander J, Gottschalk A, Zaret BL. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. AHJ 1983;106:638-43.CrossRefPubMed

10.

Plana J, Galdarisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. JASE 2014;27:911-39.

11.

Armstrong G, Joshi V, Ness K, Marwick TH, Zhang N, Srivastava D, et al. Comprehensive echocardiographic detection of treatment related cardiac dysfunction in adult survivors of childhood cancer. JACC 2015;65:2511-22.PubMedCentralCrossRefPubMed

12.

Mackey J, Clemons M, Cote C, Delgado D, Dent S, Patterson A, et al. Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008;15:24-35.PubMedCentralCrossRefPubMed

13.

Bovelli D, Plataniotis G, Roila F, ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21:V277-82.CrossRefPubMed

14.

Curigliano G, Cardinale D, Suter T, Plataniotis E, Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23:vii155-66.CrossRefPubMed

15.

Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high dose chemotherapy induced cardiotoxicity in high risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-81.CrossRefPubMed

16.

Yeh E, Vejpongsa P. Subclinical cardiotoxicity associated with cancer therapy. JACC 2015;65:2523-5.CrossRefPubMed

17.

Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al. Enalapril to prevent cardiac function decline in long term survivors of pediatric cancer expressed to anthracyclines. J Clin Oncol 2004;22:820-8.CrossRefPubMed

Title: Imaging and chemotherapy cardiotoxicity: A long-playing story still seeking precision and improved outcomes/management data
Author: William A. Van Decker, MD
Publication date: 01-02-2016
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 1/2016
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-015-0274-5

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Imaging and chemotherapy cardiotoxicity: A long-playing story still seeking precision and improved outcomes/management data

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

A quick glance at selected topics in this issue

Patient-specific tracer activity in MPI SPECT: A hands-on approach

Serial imaging and outcome prediction

Pessimistic prophets

A selection of recent, original research papers

Immortality time and serial myocardial perfusion imaging: Only those who do not die may repeat the exam

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page